Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Follow-Up Questions
What is Scienture Holdings Inc (SCNX)'s P/E Ratio?
The P/E ratio of Scienture Holdings Inc is 2.0214
Who is the CEO of Scienture Holdings Inc?
Mr. Surendra Ajjarapu is the Chairman of the Board of Scienture Holdings Inc, joining the firm since 2014.
What is the price performance of SCNX stock?
The current price of SCNX is 0.935, it has increased 5.17% in the last trading day.
What are the primary business themes or industries for Scienture Holdings Inc?
Scienture Holdings Inc belongs to Health Care industry and the sector is Health Care
What is Scienture Holdings Inc market cap?
Scienture Holdings Inc's current market cap is $19.4
Is Scienture Holdings Inc a buy, sell, or hold?
According to wall street analysts, 0 analysts have made analyst ratings for Scienture Holdings Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
